Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes

Alessandro Oriani(Istituti di Ricovero e Cura a Carattere Scientifico), C. Annaloro(University of Milan), E Pozzoli(University of Milan), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), D. Soligo(University of Milan)
British Journal of Haematology
January 1, 1996
10.1046/j.1365-2141.1996.d01-1484.x
Cited by 40

Related Papers

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
|Leukemia|2018|250